Novan, Inc. Stock News

Equities analysts expect Novan, Inc. (NASDAQ:NOVN) to post earnings per share (EPS) of ($0.42) for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Novans earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.39). Novan posted earnings of ($0.70) per share during the same quarter last year, which indicates []

BridgeBio Pharma (NASDAQ:BBIO) and Novan (NASDAQ:NOVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. Analyst Recommendations This is a breakdown of current ratings and target prices for BridgeBio Pharma and Novan, []

Equities analysts forecast that Novan, Inc. (NASDAQ:NOVN) will announce earnings of ($0.40) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Novans earnings, with estimates ranging from ($0.42) to ($0.39). Novan reported earnings of ($0.70) per share in the same quarter last year, which would suggest a []

Equities research analysts expect Novan, Inc. (NASDAQ:NOVN) to announce earnings per share (EPS) of ($0.40) for the current quarter, Zacks reports. Four analysts have provided estimates for Novans earnings, with estimates ranging from ($0.42) to ($0.39). Novan reported earnings of ($0.70) per share during the same quarter last year, which suggests a positive year-over-year growth []

– SB206 demonstrates continued favorable safety profile consistent with previous studies and meets Company's expectations –

– Live fireside chat with Paula Brown Stafford, President and Chief Executive Officer of Novan on Tuesday, September 28 at 8:00 AM ET – – Live fireside chat with Paula Brown Stafford, President

– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum –

– Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in pati

DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Nova

– Conference call with live audio webcast to be held on Thursday, September 9 th at 8:30 a.m. ET –

Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q2 2021 Results - Earnings Call Transcript

– Positive data across all three of the Company's priority pipeline development programs, announced in Q2 2021, further validating the potential of its novel, proprietary NITRICIL™ technology –

Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET Company to host conference call and webcast on Thursday, August 12, 2021, at 8:30 a.m. ET

– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less t

The stock price of Novan Inc (NASDAQ: NOVN) increased by over 10% during intraday trading. This is why it happened.